Title of Invention

A BIOCOMPATIBLE SUBSTRATE HAVING AN ELECTRON DONATING SURFACE WITH METAL PARTICLES COMPRISING PALLADIUM ON SAID SURFACE

Abstract A biocompatible substrate having an electron donating surface with metal particles comprising palladium on said surface is disclosed. The substrate comprising an electron donating surface with metal particles on said surface, wherein each metal particle comprises palladium and at least one metal selected from the group consisting of gold, ruthenium, rhodium, osmium, iridium, and platinum, wherein the amount of said metal particles on said surface is from 0.001 to 8 µg/cm2. wherein said metal particles have an average size of 10-10000 Å, wherein said particles are distributed particles on said surface from a colloidal suspension of the particles; and wherein the metal particles do not form a covering layer.
Full Text

Field of the invention
The present invention relates to a new substrate with nano
particles, which makes it possible to modify surface properties relating to biocompatibility in a repeatable
and controlled manner. Examples of surface properties,
which can be modified, include but are not limited to
hydrophobicity, protein adsorption, tissue ingrowth,
complement activation, inflammatory response,
thrombogenicity,. friction coefficient, and surface
hardness. The present invention, further relates to objects
comprising said new substrate. The present invention
further relates to the use of said substrate. Finally the
present invention further relates to a method for the
manufacture of such a substrate.
Background
It has always been desirable to modify surface
characteristics to achieve useful properties.. In
particular it is desired to be able to modify surface
properties that are important in connection with
biocompatible objects. Examples of known surface
modifications for different purposes are outlined below.
US 6,224,983 discloses an article with an adhesive,
antimicrobial and biocompatible coating comprising a layer
of silver stabilised by exposure to one or more salts of
one or more metals selected from the group consisting of
platinum, palladium, rhodium, iridium, ruthenium and
osmium. The thickness of the silver layer is in the range
2-2000A (Angstrom, Angstrom, 10-10 m) and further disclosed
ranges are 2-350A and 2-50A. There are also examples of a
thickness of the silver layer of 50A, 350A, 500A, and

1200A. The substrate may be latex, polystyrene, polyester,
polyvinylchloride, polyurethane, ABS polymers,
polycarbonate, polyamide, polytetrafluoroethylene,
polyimide or synthetic rubber.
US 5,965,204 discloses a method for preparing an article
made of a nonconducting substrate having a coating
comprising a silver layer, which has been deposited after
activating the surface with stannous ions. There is also
disclosed a coating further comprising a platinum group
metal or gold. The thickness of the silver layer is in the
range 2-2000A and further disclosed ranges are 2-350A and
2-50A. There are also examples of a thickness of the
silver layer of 50A, 350A, 500A, and 1200A.
US 5,747,178 discloses an article made by depositing a
silver layer. The layer is said to be adhesive,
antimicrobial and biocompatible. The silver layer may be
stabilized by exposure to a salt solution of one or more
platinum group metals or gold. The thickness of the silver
layer is in the range 2-2000A and further disclosed ranges
are 2-350A and 2-50A. There are also examples of a
thickness of the silver layer of 50A, 350A, 500A, and
1200A. The article may be made of latex, polystyrene,
polyester, polyvinylchloride, polyurethane, ABS polymers,
polycarbonate, polyamide, polytetrafluoroethylene,
polyimide or synthetic rubber.
US 5,395,651 discloses a method of preparing an
antimicrobial device comprising a nonconducting material
with a silver coating. The coating also comprises a
platinum group metal and/or gold. The method comprises
the steps: 1 activating the surface to be coated; 2
depositing silver on the surface; 3 treating the surface

with a salt of a platinum group metal and/or gold, which
is to be carried out for only sufficient time to result in
a thin coating; 4 rinsing with water. The treatment of
step 3 can utilise a salt of platinum or palladium in
combination with gold. Nothing is said about the thickness
of the coating of the platinum group metal and/or gold.
The coating is only described as a thin coating. Nothing
is said about metal particles on the silver coating. The
thickness of the silver layer is in the range 2-2000A and
further disclosed ranges are 2-350A and 2-50A. There are
also examples of a thickness of the silver layer of 50A,
350A, 500A, and 1200A.
US 5,320,908 discloses an adhesive, antimicrobial, and
biocompatible coating consisting essentially of a layer of
silver overlaid by one of more platinum group metals or
gold. The coating may be transparent to the human eye. The
thickness of the silver layer is in the range 2-2000A and
further disclosed ranges are 2-350A and 2-50A. There are
also examples of a thickness of the silver layer of 50A,
350A, 500A, and 1200A. The article may be made of latex,
polystyrene, polyester, polyvinylchloride, polyurethane,
ABS polymers, polycarbonate, polyamide,
polytetrafluoroethylene, polyimide or synthetic rubber.
US 5 695 857 discloses antimicrobial surfaces with several
layers of one first metal and a second nobler metal. The
antimicrobial active metal may for instance be platinum,
gold, silver, zinc, tin, antimony and bismuth. The nobler
metal may for instance be selected from the group
consisting of platinum, osmium, iridium, palladium, gold,
silver and carbon. The surface is to be used with
biological fluids and each of the layers not in contact
with the substrate are discontinuous so that the layer

below is exposed. One example of a surface is silver
coated with gold or platinum. Other examples are copper in
combination with silver, copper in combination with a
copper silver alloy, copper in combination with gold or a
silver copper alloy in combination with gold.
CH 654 738 A5 discloses surgical implants made of
stainless steel, which is coated with a first layer of
copper and a second layer of silver, gold, rhodium or
palladium. Silver is described to have a bactericidic
action. CH 654 738 A5 explicitly discloses a surface where
stainless steel is coated with lOum copper and 5um (50
000A) palladium. All surfaces disclosed in CH 654 738 A5
have a layer of lOum copper (100 000Å) and either lOum
silver or 5um gold or 5µm palladium.
WO 2005/073289 discloses fibres made of a polymer
composite comprising metal nanoparticles. It is stated
that many metals have antimicrobial effects. Antimicrobial
fibres are mentioned. One example is a hydrophilic fibre
used in antimicrobial would dressings. Fibres with
antimicrobial properties can comprise Ag, Au, Pt, Pd, Ir,
Sn, Cu, Sb, Bi or Zn or any combination thereof.
Short summary of the present invention
A problem in the state of the art regarding surfaces is
how to provide a surface which is biocompatible, wherein
it in a repeatable way is possible to modify the
hydrophobicity, protein adsorption, tissue ingrowth,
complement activation, inflammatory response,
thrombogenicity, friction coefficient, and surface
hardness.

The present inventors have discovered that the above-
mentioned problem in the state of the art is solved by a
substrate having an electron donating surface,
characterized in that there are metal particles on said
surface, said metal particles comprise palladium and at
least one metal selected from the group consisting of
gold, ruthenium, rhodium, osmium, iridium, and platinum
and wherein the amount of said metal particles is from
about 0.001 to about 8ug/cm2. Further embodiments of the
present invention are defined in the appended dependent
claims, which hereby are incorporated by reference.
Description.
Definitions
Before the invention is disclosed and described in detail,
it is to be understood that this invention is not limited
to particular configurations, process steps and materials
disclosed herein as such configurations, process steps and
materials may vary somewhat. It is also to be understood
that the terminology employed herein is used for the
purpose of describing particular embodiments only and is
not intended to be limiting since the scope of the present
invention is limited only by the appended claims and
equivalents thereof.
It must be noted that, as used in this specification and
the appended claims, the singular forms "a", "an" and
"the" include plural referents unless the context clearly
dictates otherwise.
The following terms are used throughout the description
and the claims.

"Biocompatible" as used herein is the ability of a
material to perform with an appropriate host response in a
specific application.
"Biofilm" as used herein is a thin layer in which
microorganisms are embedded. Biofilms occur when
microorganisms colonise a surface.
"Complement activation" as used herein is a complex system
of factors in blood plasma that may be activated by a
chain reaction from component C1 to C9, which give rise to
a number of biological effects. Complement activation
occurs in two ways a) the classical C1 to C9, or b) the
alternative by direct activation of C3.
"Contact angle". For a given droplet on a solid surface
the contact angle is a measurement of the angle formed
between the surface of a solid and the line tangent to the
droplet radius from the point of contact with the solid.
"Electron donating material" as used herein is a material,
which in connection with another more noble material has
the ability to transfer electrons to the more noble
material. An example is a less noble metal together with a
more noble metal.
"Electron donating surface" as used herein is a surface
layer comprising an electron donating material.
"Hydrophobicity" of a surface as used herein describes the
interactions between the surface and water. Hydrophobic
surfaces have little or no tendency to adsorb water and
water tends to "bead" on their surfaces. The term
hydrophobicity of a surface is also closely linked with

its surface energy. Whereas surface energy describes
interactions of the surface with all molecules, the
hydrophobicity describes the interactions of the surface
with water.
"Hysteresis of contact angle" as used herein is the
difference between the advancing and receding contact
angle values. The advancing contact angle of a drop of
water on a surface is the contact angle when the boundary
between water and air is moving over and wetting the
surface, while the receding angle is the contact angle
when boundary between water and air is withdrawn over a
pre-wetted surface.
"Inflammatory response" occurs when tissues are injured by
viruses, bacteria, trauma, chemicals, heat, cold or any
other harmful stimulus. Chemicals including bradykinin,
histamine, serotonin and others are released by
specialised cells. These chemicals attract tissue
macrophages and white blood cells to localise in an area
to engulf and destroy foreign substances.
"Modify" either means reducing or enhancing a property.
"Noble" is used herein in a relative sense. It is used to
relate materials including metals to each other depending
on how they interact with each other. When two metals are
submerged in an electrolyte, while electrically connected,
the term "less noble" metal is used to denote the metal
which experiences galvanic corrosion. The term "more
noble" is used to denote the other metal. Electrons will
be transferred from the "less noble" metal to the more
noble metal.

"Protein adsorption" as used herein is the phenomenon
where proteins adhere to a surface due to overall
attractive forces between the proteins and the surface.
"Substrate" as used herein is the base, which is treated
according to the present invention.
"Tissue ingrowth" is the process where cells start to grow
on a surface, forming new tissue.
"Thrombogenicity" as used herein is the ability of a
substrate to induce clotting of blood.
Detailed description of the present invention
According to the present invention a substrate is treated
to give it desired properties. The substrate can be made
of a wide range of materials. In one embodiment the
substrate is made of a material, which has an electron-
donating surface. In an alternative embodiment it is made
of a material, which does not have an electron-donating
surface. In the case of an electron-donating surface the
metal particles can be applied directly on to the
electron-donating surface. In the case where the surface
it not electron donating, a layer of an electron donating
material has to be applied to create an electron donating
surface.
The present invention comprises a substrate having an
electron donating surface, characterized in that there are
metal particles on said surface, said metal particles
comprise palladium and at least one metal selected from
the group consisting of gold, ruthenium, rhodium, osmium,
iridium, and platinum and wherein the amount of said metal
particles is from about 0.001 to about 8 µg/cm2. A

preferred amount of said metal particles is from about
0.01 to about 4 µg/cm2. A particularly preferred amount of
said metal particles is from about 0.01 to about 1 µg/cm2.
Either the substrate itself is electron donating or there
is applied a layer of an electron donating material on the
substrate. In the case where the electron donating
material is applied on the substrate it is applied in an
amount of from about 0.05 to about 12 µg/cm2.
An electron donating material does not necessarily have an
electron-donating surface. An example is aluminium, which
in air gets an oxide layer, which is not an electron-
donating surface.
The electron donating material is any material with the
ability to form an electron-donating surface, such as a
conducting polymer or a metal. In the case of a metal it
must be less noble than any of the metals in the group
consisting of palladium, gold, ruthenium, rhodium, osmium,
iridium, and platinum.
A preferred metal for use as an electron-donating surface
is a metal selected from the group consisting of silver,
copper and zinc.
In one embodiment of the present invention the substrate
is a polymeric substrate.
In one embodiment the substrate is selected from the group
consisting of latex, vinyl, polymers comprising vinyl
groups, polyurethane urea, silicone, polyvinylchloride,
polypropylene, styrene, polyurethane, polyester,
copolymerisates of ethylene vinyl acetate, polystyrene,

polycarbonate, polyethylene, polyacrylate,
polymethacrylate, acrylonitrile butadiene styrene,
polyamide, and polyimide, or mixtures thereof.
In another embodiment of the present invention the
substrate is selected from the group consisting of a
natural polymer, a degradable polymer, an edible polymer,
a biodegradable polymer, an environmental friendly
polymer, and a medical grade polymer.
In another embodiment of the present invention the
substrate is a metal.
A preferred metal for the substrate is selected from the
group consisting of stainless steel, medical grade steel,
titanium, medical grade titanium, cobalt, chromium and
aluminium or mixtures thereof.
In another embodiment of the present invention the
substrate is selected from the group consisting of glass,
minerals, zeolites, stone and ceramics.
In another embodiment of the present invention the
substrate is selected from the group consisting of paper,
wood, woven fibres, fibres, cellulose fibres, leather,
carbon, carbon fibres, graphite, polytetrafluoroethylene,
and polyparaphenyleneterephthalamide.
In another embodiment of the present invention the
substrate has the shape of a particle.
In one embodiment of the present invention there is
provided an object comprising a substrate according to the
present invention. Examples of an object comprising a

substrate according to the present invention are medical
devices, medical instruments, disposable articles, medical
disposable articles.
The particles must always comprise palladium. In addition
to palladium there is at least one other metal. A ratio of
palladium to other metals in the metal particles of from
about 0.01:99.99 to about 99.99:0.01 can be used in the
present invention. A ratio from about 0.5:99.5 to about
99.8:0.2 is preferred. Particularly preferred ratios are
from about 2:98 to about 95:5. Very particularly preferred
ratios are 5:95 to 95:5. In another embodiment the ratios
are from about 10:90 to about 90:10.
In one embodiment of the present invention said metal
particles, in addition to palladium, comprise gold.
The present inventors have discovered that advantageous
properties are achieved when said metal particles have an
average size of from about 10 to about 10000A.
In one embodiment the average sizes for said metal
particles are from about 100 to about 600A.
In another aspect of the present invention there is
provided an object comprising any of the substrates
described herein.
There is also provided a medical device comprising any of
the substrates described herein.
A disposable article comprising any of the substrates
described herein is also provided.

The present invention also provides a dental article, as
well as dental equipment, dental implants, and dental
devices, comprising any of the substrates described
herein.
The applied amount of the metal particles is expressed in
µg/cm2 and it must be realised that the metal particles do
not form a covering layer, but instead are uniformly
distributed particles or clusters on said electron
donating surface.
An applied layer of an electron donating material is
preferably applied so that it is uniform, essentially
without agglomerates or clusters on the surface. If the
electron donating surface layer is homogenous and uniform
the applied amount in µg/cm2 may be converted to a
thickness in A. An applied amount of 0.05-4ug/cm2
corresponds to about 4.8-380A, 0.5-8ug/cm2 corresponds to
about 48-760A, and 0.8-12ug/cm2 corresponds to about 76-
1140A.
In one embodiment of the present invention the electron-
donating surface is a layer of commercially available
essentially pure silver, which does not exclude the
possibility of small amounts of impurities.
If the substrate does not have an electron donating
surface and thus a deposition of an electron donating
surface layer is necessary, the deposition is performed
using a method selected from the group consisting of
chemical vapour deposition, sputtering, and deposition of
metal from a solution comprising a metal salt. A uniform
layer essentially without clusters or agglomerates is the
result of the deposition. Preferably the deposition is

carried out so that the first layer has good adhesion to
the substrate.
Now there is described one embodiment of the present
invention for preparation of the coated substrate. For
substrates which do not have an electron donating surface
the method include some or all the steps:
1. pre-treatment
2 . rinsing
3. activation
4. deposition of an electron donating surface
5. rinsing
6. deposition of metal particles
7. rinsing
8. drying
For objects with an electron-donating surface the method
comprises the steps
1. rinsing
2. deposition of metal particles
3. rinsing
4. drying
In the following, one embodiment of steps 1 to 9 for
substrates which do not have an electron-donating surface
is described more in detail.
The pre-treatment can be made in an aqueous solution of a
stannous salt containing 0.0005 to 30 g/1 of stannous
ions. The pH is 1 to 4 and adjusted by hydrochloric and/or
sulphuric acid. The treatment time is 2-60 minutes at room
temperature. After the pre-treatment the surface is rinsed
in demineralised water, but not dried.

The activated and rinsed substrate is transferred to the
deposition solution. The deposition solution has a pH of
not less than 8. It includes a metal salt selected from
the group consisting of a silver salt, a zinc salt, and a
copper salt. In one embodiment of the present invention
the salt is silver nitrate (AgNO3) . The metal salt is used
in an effective amount of no more than about 0.10 grams
per litre, preferably about 0.015 grams per litre. If the
metal content is above,about 0.10 grams per litre, the
elemental metal may form nonuniformly, in the solution or
on the container walls. If the metal content is below an
effective amount, there is insufficient metal, to form a
film in the desired time.
A second component of the deposition solution is a
reduction agent that reduces the metal-containing salt to
elemental metal. The reduction agent must be present in an
amount sufficient to accomplish the chemical reduction.
Acceptable reduction agents include formaldehyde,
hydrazine sulphate, hydrazine hydroxide, and hypo
phosphoric acid. In one embodiment of the present
invention it is present in an amount of about 0.001
millilitres per litre of solution. Too large a
concentration of the reduction agent causes deposition of
metal throughout the solution and on the container walls,
while too small a concentration may result in an
insufficient formation of metal on the substrate. A person
skilled in the art can in the light of this description by
routine experimentation determine the desired amount of
reduction agent.
Another component of the deposition solution is a
deposition control agent that is present in an amount
sufficient to slow the deposition reaction to prevent the

reduced metal from precipitating directly from solution as
a fine metallic powder, or precipitating onto the walls of
the container. Operable deposition control agents include
inverted sugar, also known as invertose, succinic acid,
sodium citrate, sodium acetate, sodium hydroxide,
potassium hydroxide, sodium tartrate, potassium tartrate,
and ammonia. The deposition control agent is preferably
present in an amount of about 0.05 grams per litre of
solution. If too little is present, there may occur
precipitation of metal clusters instead of a uniform
metallic surface. If too much is present, the metal-
containing salt may become too stable for the desired
precipitation onto the substrate of interest.
The concentrations of the reduction agent and the
deposition control agent are adjusted as necessary to
achieve the desired results, depending upon the substrate
material, the thickness of the film desired, the
conditions of deposition, and the concentration of metal
in the solution. For example, for thin films the metal
salt concentration will be relatively low, as will the
concentrations of the reduction agent and the deposition
control agent. A person skilled in the art can in the
light of this description by routine experimentation
determine the desired amount of deposition control agent.
In preparing the deposition solution, each of the
components of the solution are preferably individually
dissolved in demineralised water. The various pre-
solutions are then mixed, and diluted where necessary, in
the correct amounts to achieve the concentrations
mentioned above.
The combination of a metal salt and reduction agent

permits the metal to be reduced from the salt in a
suitable state to be deposited upon the surface of the
substrate. This method is particularly beneficial to
achieve good adhesion of the completed metal film to the
substrate surface. Good adhesion is important in nearly
all uses.
The substrate surface is exposed to the deposition
solution by any appropriate procedure. Dipping into the
solution is normally preferred, but the solution may be
applied by any convenient technique such as spraying or
brushing. The metal film deposits uniformly from the
solution at a rate that may be controlled by the
concentration of the metal salt. If a thin film is
required, the temperature of deposition is maintained
sufficiently low so that deposition is controllably slow.
Other methods of applying a metal layer that acts as an
electron-donating surface can also be applied in the
present invention. Other ways of achieving an electron-
donating surface are chemical vapour deposition and
sputtering.
After the above-described metal deposition the substrate
has an electron-donating surface consisting of a metal.
This metal deposition is only necessary if the substrate
does not have an electron-donating surface from the start.
If the substrate already possesses an electron-donating
surface, metal particles can be deposited on the surface
without the extra addition of a metal layer. In the latter
case the substrate is cleaned thoroughly before
application of the particles.

The next step in the manufacturing method is deposition of
metal particles.
In one embodiment colloidal suspensions of metals are used
to obtain particles comprising palladium and at least
another metal on the surface. The metal particles are
deposited from a suspension of the desired particles. The
composition of the metal particles in the suspension is
adjusted according to the preferred value. The substrate
with the electron-donating surface is dipped in the
suspension of metal particles for a period of time from
about a few seconds to about a few minutes or longer.
The suspension of metal particles can be manufactured in
several ways. In one embodiment the suspension of metal
particles is made from an aqueous solution of a metal salt
which is reduced under conditions such that metal
particles of a desired size are formed. Mixing a suitable
amount of metal salt, reducing agent and stabilising agent
achieves this. The same reducing agents and stabilising
agents as described above can be used when making the
particle suspension. A person skilled in the art can in
the light of this description by routine experimentation
determine the desired amount of reducing agent and
stabilising agent to get the desired particle size. In an
alternative embodiment a commercially available colloidal
suspension of metal particles is used. Metal particles of
the desired composition are used to make the suspension.
In one embodiment the suspension of metal particles is
made by diluting with demineralised water a commercially
available concentrated colloidal solution of metal
particles comprising palladium and at least one metal
selected from the group consisting of gold, ruthenium,

rhodium, osmium, iridium, and platinum. The substrate is
treated with the suspension for a period of time from
about a few seconds to about a few minutes or longer.
After the treatment the substrate is rinsed in a solvent
or water such as demineralised water and left to dry in
room temperature.
In one particular non-limiting embodiment the commercially
available metal particles consist of 75% palladium and 25%
gold.
Thus according to the present invention, a substrate with
a particular desired surface can be obtained. For example,
one can prepare a substrate having a silver electron
donating surface with particles consisting of 75%
palladium and 25% gold, or a copper electron donating
surface with particles consisting of 85% palladium and 15%
ruthenium.
One of the advantages offered by the flexible yet
controlled and repeatable method for producing such
substrates is that a wide variety of substrates can be
produced. As described further herein, certain substrates
have improved properties over existing substrates. For
example a particular substrate according to the present
invention can produce surprising and advantageous
modifications of the hydrophobicity of a substrate to
which is it applied. Other properties that can be modified
in this way by substrates according to claim 1 include
protein adsorption, tissue ingrowth, complement
activation, inflammatory response, thrombogenicity,
friction coefficient, and surface hardness.

That is, it is possible to adjust the particle size, the
composition of the particles and the amount of particles
to modify the surface properties of objects to which the
substrate is applied.
The present inventors have discovered that it is possible
to achieve this by using a substrate according to claim 1.
In particular it is possible to adjust the particle size,
the composition of particles, and the amount of particles
to modify the surface properties.
Substrates according to the present invention can be used
for many purposes. They are suitable for use in any
application where it is desired to modify hydrophobicity,
protein adsorption, tissue ingrowth, complement
activation, inflammatory response, thrombogenicity,
friction coefficient, and surface hardness of a substrate.
Properties of the substrate can be both reduced or
increased. Thus objects are provided which display at
least one area which enhances a feature, and at least one
area which reduces a feature. An example is an object with
an area that reduces protein adsorption and an area that
enhances protein adsorption. Another example is an object
with an area that reduces tissue ingrowth and an area that
enhances tissue ingrowth.
A substrate according to the present invention also
comprises a substrate having an electron donating surface,
with metal particles on said surface, said metal particles
comprise palladium wherein the amount of said metal
particles is from about 0.001 to about 8 µg/cm2.

The present invention provides use of a substrate
according to the present invention for modifying the
protein adsorption to an object comprising said substrate.
The present invention provides use of a substrate
according to the present invention for modifying the
tissue ingrowth on an object comprising said substrate.
The present invention provides use of a substrate
according to the present invention for modifying the
complement activation caused by an object comprising said
substrate.
The present invention provides use of a substrate
according to the present invention for modifying the
inflammatory response caused by an object comprising said
substrate.
The present invention provides use of a substrate
according to the present invention for modifying the blood
clotting caused by an object comprising said substrate.
Another advantage of the substrate according to the
appended claims is that it provides a possibility to
modify the friction coefficient. Thus there is provided
the use of a substrate according to the present invention
for the modification of the friction coefficient of an
object comprising said substrate.
Other features of the invention and their associated
advantages will be evident to a person skilled in the art
upon reading the description and the examples.

It is to be understood that this invention is not limited
to the particular embodiments shown here. The following
examples are provided for illustrative purposes and are
not intended to limit the scope of the invention since the
scope of the present invention is limited only by the
appended claims and equivalents thereof.
Examples
Example 1
Hydrophobicity of the surface as a function of the amount
of metal particles
A uniform layer of silver was deposited on a glass
substrate according to the following method. The substrate
was immersed in a cleaning solution of chromic acid for 5
minutes at 58°C, followed by rinsing in demineralised
water. The surface of the substrate was activated by
immersion in a solution of aqueous stannous chloride and
then rinsed in demineralised water. The surface of the
substrate was then plated with a uniform layer of silver
by immersion in 3 deposition solutions comprising silver
ions. This yielded a silver surface with an applied amount
of 1.2ug/cm2 corresponding to a thickness of about 115A.
Particles consisting of 23% palladium and 77% gold were
subsequently deposited on the first silver surface by
immersion in a dilute suspension comprising metal
particles of gold/palladium. The suspension of metal
particles was made by reducing a gold salt and a palladium
salt with a reducing agent and stabilising the suspension
with a stabilising agent. The substrate was subsequently
rinsed in demineralised water and dried.

Substrates with different amounts of deposited particles
were made using the method outlined above. Amounts of
particles were 0, 0.02, 0.11, 0.15, and 0.19 µg/cm2
respectively. For the sample with 0 µg/cm2 no particles
were deposited on the surface and hence it consists of a
silver surface.
The static contact angle of a drop of water in equilibrium
on the different substrates was measured. The advancing
and receding contact angles were measured using the
Wilhelmy technique.
The difference between the advancing and receding contact
angle values is called the contact angle hysteresis and
was calculated for the measurements. The result of the
experiment is depicted in Table 1.

The surface hydrophobicity of the substrate is thus
modified while the surface displays several other useful
properties, such as biocompatibility, inherent of the
substrates according to this example.
Example 2

Protein adsorption as a function of the amount of metal
particles
A uniform layer of silver was deposited on a silicon
dioxide substrate. The substrate was immersed in a
cleaning solution of 20% sulphuric acid for 10 minutes at
room temperature, followed by rinsing in demineralised
water. The surface of the substrate was activated by
immersion in an aqueous solution of stannous chloride and
the rinsed in demineralised water. The surface of the
substrate was then plated with a uniform layer of silver
by immersion in 4 baths of deposition solutions comprising
silver ions. This yielded a silver surface with an applied
amount of 0.8 µg/cm2 corresponding to a thickness of about
77 A. Particles consisting of 95% palladium and 5% gold
were subsequently deposited on the first silver surface by
immersion in a dilute suspension of Pd/Au-particles. The
applied amount of metal particles was 0.05, 0.12, 0.4 8 and
0.59 µg/cm2 respectively. The substrate was rinsed in
demineralised water and dried.
Adsorption of fibrinogen was studied by the QCM-D
technique. Fibrinogen is a glycoprotein synthesised in the
liver and is found in blood plasma. QCM-D is a quartz
crystal microbalance with dissipation monitoring.
The adsorbed amount of fibrinogen as a function of applied
metal particles is shown in table 2.


Example 3
A net of polyester fabric was first rinsed in a 5%
potassium hydroxide solution for 5 min at 30°C. After
repeated rinsing in demineralised water the substrate was
immersed in an acidified solution of 1 g/l stannous
chloride at room temperature for 10 min. After rinsing in
demineralised water it was soaked in a plating bath
containing 2 g/l copper sulphate, 5 g/l sodium hydroxide,
50 g/l sodium citrate and 0.005 ml/1 formaldehyde for 10
min at 35°C. A copper layer of about 200 A was obtained
and after new rinsing in demineralised water the substrate
was immersed in a particle suspension comprising 0.05 g/l
each of palladium particles and gold particles. The
applied amount of metal particles was 0.4 µg/cm2.
Example 4
A substrate of PMMA was cleaned in 5% hydrochloric acid
for 2 min and then rinsed in demineralised water before
dipping in a solution containing 0.02 g/l of the stannous
ion at a pH of 2.5. After rinsing the substrate was
immersed in a solution containing 0.005 g/l of silver
ions, 0.02 ml/1 ammonia, 0.05 g/l potassium hydroxide and
0.0005 ml/1 formaldehyde for 5 min at room temperature.
This gave a surface with 0.12 µg/cm2 of silver. After
rinsing it was immersed in a particle suspension

comprising 0.005 g/l palladium and 0.002 g/l gold
particles. The applied amount of metal particles was 0.05
µg/cm2.
Example 5
A non-woven polyimide substrate was immersed in a 12%
solution of NaOH at 40°C for 10 min. After repeated
rinsing in demineralised water it was immersed in an
alcoholic solution containing 0.5 g/l stannous chloride
for 5 min at room temperature. After rinsing it was soaked
in a copper bath according to example 3. A copper layer of
2 µg/cm2 was obtained. After rinsing it was immersed in a
suspension comprising 1% of Pd and 0.2% of gold particles,
calculated on the weight of the total suspension. The
applied amount of metal particles was 0.6 µg/cm2.
Example 6
A nylon fabric was cleaned in 5% NaOH for 10 min at 40°C
and after rinsing in demineralised water immersed in a
solution of 0.6 g/l stannous chloride at pH 2.2 for 15 min
at room temperature. After this the surface comprised a
silver amount of 0.8 µg/cm2. After a new rinsing it was
dipped in a silver bath according to example 2 and then
after new rinsing dipped in a suspension comprising 1% Pd
and 0.05% Au particles. The applied amount of metal
particles was 0.12 µg/cm2.
Example 7
A substrate of aluminium was treated in a solution of 10%
nitric acid and 3% hydrofluoric acid at 60°C for 20 min.
After rinsing, the substrate was dipped in an acidified
solution of 3 g/l stannous chloride and after renewed
rinsing in a silver bath according to example 2. After
this step an amount of around 80 A silver was obtained on

the surface. After another rinsing the substrate was
immersed in a suspension comprising 1% Pd and 2% Au
particles. The applied amount of metal particles was 0.7
µg/cm2.
Example 8
A substrate of PTFE was etched in an aqueous solution of
sodium hydroxide for 5 min. After rinsing and drying it
was immersed in a solution containing 0.7 g/l stannous
chloride for 20 min at room temperature. The substrate was
after rinsing dipped in a plating bath containing 0.2 g/l
silver nitrate, 0.5 ml/1 ammonia and sodium hydroxide to
pH 10.5 for 5 min. After this step an amount of around 2.2
µg/cm silver was obtained on the surface. After a new
rinse it was immersed in a suspension comprising 3% Pd and
0.1% Au particles for 5 min at room temperature. The
applied amount of metal particles was 0.03 µg/cm2.
Example 9
A glass plate was rinsed in 10% sulphuric acid and 1%
hydrofluoric acid at room temperature for 15 min. After
rinsing it was immersed in a 1% stannous fluoride solution
and after a new rinse immersed in a silver bath according
to example 2. After this step an amount of around 140 A
silver was obtained on the surface. After renewed rinsing
it was dipped in a suspension comprising 1% ruthenium and
2% palladium particles. The applied amount of metal
particles was 0.25 µg/cm2.
Example 10
A stainless steel substrate was immersed in a solution of
15% nitric acid and 5% HF at room temperature for 30 min
and then rinsed in demineralised water. The process

continued following the steps in example 11. The applied
amount of metal particles was 0.9 µg/cm2.
Example 11
A titanium rod was cleaned in a solution of 18% nitric
acid and 2% HF for 20 min at room temperature. The
application of an electron donating surface and the
application of metal particles was made as in example 11.
The applied amount of metal particles was 0.6 µg/cm2.
Example 12
Detection of surface induced complement activation with
Quartz Crystal Microbalance with dissipation monitoring
(QCM-D)
The quantification of a foreign body response is
indirectly achieved by monitoring the binding of rabbit-
anti human antibodies directed to the surface bound
complement factor C3b.
Within seconds from introduction to a soft tissue a
foreign body is subject to great attention from the
complement system. The complement system comprises about
30 different proteins where C3 is the most abundant. After
high concentration body fluid proteins (i.e. Albumin,
Fibrinogen and Fibronectin) the complement system is one
of the first actors on the scene and aims to protect the
host from invading bacteria and fungi, but also to alert
the immune system about a foreign body entering the
system.
Without being bound by any specific scientific theory the
inventors assume that when complement factor 3 (C3) binds
to an introduced surface it is cleaved by C3 convertase to

form soluble C3a, and surface bound C3b. The surface bound
C3b will then act as a convertase itself, triggering
subsequent cleavage of C3 in a cascade-like fashion.
Receptors to C3b is found on erythrocytes, macrophages,
monocytes, polymorphonulear leukocytes and B cells, all of
which are important in controlling inflammation and wound
healing in tissue. The exact mechanisms controlling the
binding of C3 to the surface are still much unknown.
However, antibodies directed specifically towards C3b can
easily be measured in vitro with QCM-D and give
quantitative information of a biomaterial's immune
response properties. This new methodology show good
agreement with all other known methods for the detection
of surface bound C3b.
Material and methods
Preparation of surfaces
As model surfaces standard QCM-D crystals sputtered with
Au (s), Ti (s) (QSX301 and QSX310 respectively) was used.
A coating according to the present invention was applied
on standard SiO2 QCM-D crystals (QSX 303, Q-Sense Sweden)
using the method outlined in example 2.
Blood products
We received fresh whole blood from five healthy donors
(Sahlgrenska University Hospital, Goteborg, Sweden). The
blood was left to clot in room temperature for
approximately 4 hours to obtain complement active serum.
The serum was then centrifuged at 4 00 0 rpm for 20 min
(Hettich Universal 16 R) after which the supernatant was
removed and re-centrifuged as above and stored at -70 °C.

For detection of surface induced complement activation the
serum was diluted 1:5 in Veronal Buffer Saline
supplemented with CaCl2 (0.15 mM) and MgCl2 (0.5 mM)
(VBS++) , and the adsorption of serum proteins to the
modified QCM-D-crystals were monitored for 20 minutes
followed by a rinse with buffer for 5 minutes. The rinse
was followed by the addition of rabbit-anti-human C3b
antibodies diluted 1:20 in VBS++ (Sigma). For negative and
positive controls, standard gold QCM-D crystals pre-coated
with human IgG (lmg/ml) (Sigma) were used. The negative
control was heat inactivated at 56°C for 30 min prior to
measurements.
All experiments were carried out at room temperature in
Veronal Buffer Saline with CaCl2 (0.15 mM) and MgCl2 (0.5
mM) (VBS++) except for negative controls were VBS- - were
used. All QCM-D measurements were preformed on the
apparatus D300 (Q-sense, Sweden).
Results
The SiO2 surfaces coated as described above had an amount
of silver of 0.35-0.61 µg/cm2. The amount of gold in the
particles was varied according to the table below and the
complement activation was measured according to the table.


Example 13
Platelet adhesion and soluble complement factor C3a
production on biomaterial surfaces
The consumption of platelets in fresh whole blood exposed
to a biomaterial is used to quantify the thrombogenicity
of a desired biomaterial. Moreover, the soluble fraction
of activated complement factor 3 (C3a) is used to monitor
the complement activation from the biomaterial surface.
Background
Platelets (or thrombocytes) are small disc-shaped anuclear
cell fragments normally present in healthy blood. They
play a crucial role in preserving the walls in blood
vessels and are recruited to a damaged area and activated
to form a plug, preventing hemorrhage and blood loss.
Platelets are also known to adhere and become activated on
certain biomaterial surfaces, sometimes forming an
undesired and potentially hazardous clot.
Soluble C3a is a small protein cleaved off from the
complement factor 3 (C3) when this is bound and activated
on a bacteria or a foreign body surface. C3a acts as a
chemo-attractant for polymorphonuclear (PMN) monocytes and
also have anaphylatoxic properties signalling for the
release of histamine from mast cells.
Material and methods
Experimental chambers
The experimental chamber is briefly constructed of two
PMMA rings glued onto a PMMA microscopic slide,
constructing two wells. After addition of whole blood, the
material to be tested is placed as a lid over the two
wells and held in position with a clip. The chamber is

then mounted on a disc rotating in 37°C water for 60
minutes at 22 rpm.
Blood
Blood was drawn from one healthy donor and collected in a
2x heparinized vial containing soluble heparin (Leo
Pharma), to give a final concentration of 1.0 IU
heparin/ml. The collected blood was then immediately
transferred to the experimental chambers.
Platelet counting
After incubation in the experimental chamber the blood was
added EDTA (Fluka) to a final concentration of 4mM.
Platelets were then counted on a Coulter AcT diff™
(Coulter Corporation) automated cell counter.
C3a analysis
After platelet counting, the blood was centrifuged at 4600
g for 10 min at +4°C and the supernatant (plasma) was
saved and stored in -70°C prior to measurements.
Plasma was diluted 1/300 and analysed in a sandwich ELISA
which employs the monoclonal 4SD17.3 (Uppsala university,
Sweden) as capture antibody. Bound C3a was detected with
biotinylated rabbit anti-human C3a (Dako), followed by
HRP-conjugated streptavidin (Amersham Biosciences).
Zymosan-activated serum, calibrated against a solution of
purified C3a, served as a standard.
Results
The coated objects manufactured following the method
outlined in example 2 on glass had a silver surface
concentration of about 1.3 µg/cm2.


Blood platelet count and C3a adsorption. The coatings on
glass had a silver surface concentration of about 1.3 µg/cm2.

Example 14
Measurement of inflammatory response
Material
NHSp-2 (Normal human serum pool from Immunologisk
institutt, Rikshospitalet, Oslo , Norway), serum from
helthy blood donors.
30 cm tubes made of PDMS (Polydimethylsiloxane) were
coated according to the procedure outlined in example 2.
30cm PVC tubes were used as control.

Setup: 7 types of tubes, untreated and PVC in triplicate
(in total 21).
Method:
1) The serum was placed on ice.
2) A zero sample was removed. 750 ul was added directly
to a tube with 15ul EDTA 0.5M. The sample was kept on
ice.
3) 750 ul serum was added to each tube.
4) The tubes were attached to a rotor (5 rpm) 37°C and
were incubated for 30 minutes.
5) The serum was removed with a pipette and added to a
tube with 15ul EDTA 0.5M. The samples were placed on
ice and analysed with respect to TCC (the soluble
terminal C5b-9 complement complex).
TCC was analyzed using a double antibody enzyme
immunoassay based on the monoclonal aEll antibody, highly
specific for a neoepitope exposed on activated but not
native C9, as catching antibody. The method was originally
described in:
Mollnes TE, Lea T, Fr0land SS, Harboe M. "Quantification of
the terminal complement complex in human plasma by an
enzyme-linked immunosorbent assay based on monoclonal
antibodies against a neoantigen of the complex", Scand J
Immunol 22:197-202. 1985.
and later modified in:

Mollnes TE, Redl H, HØgasen K, Bengtsson A, Garred P,
Speilberg L, Lea T, Oppermann M, Gotze 0, Schlag G.
"Complement activation in septic baboons detected by
neoepitope specific assays for C3b/iC3b/C3c, C5a and the
terminal C5b-9 complement complex (TCC)", Clin Exp Immunol
91:295-300. 1993.


Example 15
Cell adhesion in vitro and in vivo
Primary normal human dermal fibroblasts (NHDF, Karocell
Tissue Engineering AB, Stockholm, Sweden), passage 7, were
used. The cells were cultured in tissue culture flasks in
complete fibroblast medium containing DMEM+GlutaMAX™-1
(Gibco, UK), 10% foetal bovine serum (FBS, Gibco, UK) and
1% Antibiotic-Antimyocotic (Gibco, UK) at 37°C, 5% CO2 and
95% humidity. Ten different substrates of silicon dioxide
were coated following the method outlined in example 2 and
were sterilely punched into discs with a diameter of 15 mm
to fit in a 24-well plate. Discs were dipped in sterile
PBS (Phospate buffered saline solution, Gibco, UK) and 1
ml of cell suspension (17000 cells/ml) was dispersed over
the silicon dioxide disks and in empty PS-wells
(polystyrene, Falcon, BD Biosciences, Belgium) and
incubated for 24 h and 72 h in triplicates. Medium from
all samples were collected, centrifuged at 400g, 5 min and
stored at -70° C for ELISA (enzyme-linked immunosorbent
assay) analyses of cell released factors. Two discs of
each material were incubated with complete medium without
cells to estimate background values.
Cell amount
Cell amounts in association with the surfaces and
surrounding medium were determined by a NucleoCounter®-
system (ChemoMetec A/S, Denmark). Briefly, cells were
treated with lysis buffer and stabilizing buffer (provided
with the system). Lysed samples were loaded in a
NucleoCassette™ precoated with fluorescent propidium
iodide that stains the cell nuclei, and were then
quantified in the NucleoCounter®.

Cell viability
Cell viability was determined by measuring lactate
dehydrogenase content (LDH) in medium, a marker of cell
membrane injury, using a spectrophotometry evaluation of
LDH mediated conversion of pyruvic acid to lactic acid (C-
Laboratory, Sahlgrenska University Hospital, Goteborg,
Sweden).
Cytokine determination
The amount of TGF-β1 (Transforming Growth Factor beta 1)
and type I collagen were detected by ELISA kits (Human
TGF-β1, Quantikine®, R&D Systems, UK; Human collagen typel
ELISA KIT, Cosmo Bio Co., Japan) according to the
manufacturer's instruction, in a SpectraVmax ELISA reader
(Molecular Devices, UK).
In vivo
Six different substrates of silicon dioxide (10 mm in
diameter) were coated using the method outlined in example
2 and sterilized. Female Spraque-Dawley rats (200-250 g),
fed on a standard pellet diet and water were anaesthetized
with a mixture of 2,7% isofluran and air (Univentor 400
Anaesthesia Unit, Univentor, Malta) and 0.01 mg Temgesic
was given as analgesic s.c. pre-operatively. Rats were
shaved and cleaned with 5 mg/ml chlorohexidine in 70%
ethanol and each rat received one of each implant type
subcutaneously (s.c.) on the back. The wounds were closed
with 2 sutures (Ethilon 5-0 FS-3, Ethicon®, Johnson &
Johnson, Belgium). The implantation periods were 1 and 3
days to evaluate the early inflammatory process and 21
days for the examination of the fibrous capsule formation
and the late inflammatory response (n=8 rats per time
period). When the explantation was performed the animals
were sacrificed by an overdose of pentobarbital (60 gL-1)

after short anaesthetics with a mixture of 2,7% isofluran
and air. The implants and the surrounding exudates were
retrieved. The exudate cells were obtained from the
pockets by repeated aspiration of HBSS (Hank's balanced
salt solution, Gibco, UK) and kept on ice. The exudates
were centrifuged at 400g, 5 min and supernatants were kept
at -70°C. All implantation studies were approved by the
Local Ethical Committee for Laboratory Animals.
Cell amount and cell type
The concentration and type of cells in the exudates
(cells/ml) were counted by light microscopy with Turk
staining in a Biirker chamber and cell amount in
centrifuged exudates and on implants were determined by
NucleoCounter®-system.
Cell viability
Cell viability was determined by Trypan Blue exclusion
using light microscopy and by LDH evaluation (C-
Laboratory, Sahlgrenska University Hospital, Goteborg,
Sweden).
Cytokine determination
The amount of TGF-β1 (Transforming Growth Factor beta 1)
and MCP-1 (Monocyte Chemoattractant Protein-1) were
detected by ELISA kits (Rat TGF-β1, Quantikine®, R&D
Systems, UK; Amersham Monocyte Chemoattractant Protein-1
[(r)MCP-l], Rat, Biotrak ELISA System, GE Healthcare, UK)
according to the manufacturer's instruction, in a
SpectraVmax ELISA reader (Molecular Devices, UK).
Results from the in vitro study
The amount of metals on the test object was; Ag: 0.8-0.9
µg/cm2 and Pd: 0.1 µg/cm2.

Surface concentration of Au Number of cells after
(µg/cm2) 72 h
0.05 5500
0.34 9400
0.43 16200
In the second experimental set the amount of metals on the
test object was; Ag: 0.8-0.9 µg/cm2 and Au: 0.05-0.09 µg/cm2.
Surface concentration of Pd Number of cells after
(ug/cm2) 72 h
0.1 5500
0.27 8600
0.69 9900
Results from the in vivo study
The. Amount of Pd was varied on discs in vivo. The amount
of Ag was about 1 µg/cm2 for all samples. (PMN =
polymorphonuclear)



The Amount of Au was varied on discs in vivo. The amount
of Ag was about 1 µg/cm2 for all samples. (PMN =
polymorphonuclear)



The applicant asserts that no biological material of Indian
origin has been used in the present invention.

WE CLAIM :
1. A substrate comprising an electron donating surface with metal particles on
said surface, wherein each metal particle comprises palladium and at least one
metal selected from the group consisting of gold, ruthenium, rhodium, osmium,
iridium, and platinum, wherein the amount of said metal particles on said surface
is from 0.001 to 8 µg/cm2. wherein said metal particles have an average size of
10-10000 A, wherein said particles are distributed particles on said surface from
a colloidal suspension of the particles; and wherein the metal particles do not
form a covering layer.
2. The substrate as claimed in claim 1, wherein said electron donating surface
is a layer of an electron donating material which is applied in an amount of 0.05
to 12 µg/cm2.
3. The substrate as claimed in claim 2, wherein said electron donating layer is
a metal that is less noble than any of the metals in the group consisting of
palladium, gold, ruthenium, rhodium, osmium, iridium, and platinum.
4. The substrate as claimed in claim 3, wherein said electron donating layer is
a metal selected from the group consisting of silver, copper and zinc.
5. The substrate as claimed in anyone of claims 1 to 4, wherein said substrate
is a polymeric substrate.
6. The substrate as claimed in claim 5, wherein said polymeric substrate is
selected from the group consisting of latex, vinyl, polymers comprising vinyl
groups, polyurethane urea, silicone, polyvinylchloride, polypropylene, styrene,
polyurethane, polyester, copolymerisates of ethylene vinyl acetate, polystyrene,
polycarbonate, polyethylene, polyacrylate, polymethacrylate, acrylonitrile
butadiene styrene, polyamide, and polyimide, or mixtures thereof.

7. The substrate as claimed in claim 5, wherein said polymeric substrate is
selected from the group consisting of a natural polymer, a degradable polymer,
an edible polymer, a biodegradable polymer, an environmental friendly polymer,
and a medical grade polymer.
8. The substrate as claimed in any one of claims 1 to 4, wherein said substrate
is a metal.
9. The substrate as claimed in claim 8, wherein said metal is selected from the
group consisting of stainless steel, medical grade steel, titanium, medical grade
titanium, cobalt, and chromium or mixtures thereof.
10. The substrate as claimed in anyone of claims 1 to 4, wherein said substrate
is selected from the group consisting of glass, minerals, zeolites, stone and
ceramics.
11. The substrate as claimed in anyone of claims 1 to 4, wherein said substrate
is selected from the group consisting of paper, wood, woven fibres, fibres,
cellulose fibres, leather, carbon, carbon fibres, graphite, polytetrafluoroethylene,
and polyparaphenyleneterephthalamide.
12. The substrate as claimed in anyone of claims 1 to 11, wherein said substrate
has the shape of a particle.
13. The substrate as claimed in anyone of claims 1 to 12 wherein the amount of
the metal particles is from 0.01 to 4 µg/cm2.
14. The substrate as claimed in any one of claims 1 to 13, wherein the ratio of
palladium to non-palladium metals in said metal particles is from 0.01 : 99.99 to
99.99 :0.01.

15. The substrate as claimed in any one of claims 1 to 13, wherein the ratio of
palladium to non-palladium metals in said metal particles is from 0.5 : 99.5 to
99.8 : 0.2.
16. The substrate as claimed in any one of claims 1 to 13, wherein the ratio of
palladium to non-palladium metals in said metal particles is from 2 : 98 to 95 : 5.
17. The substrate as claimed in any one of claims 1 to 16 wherein said metal
particles, in addition to palladium, comprise gold.
18. The substrate as claimed in any one of claims 1 to 18, wherein said metal
particles have an average size of 100-600 A.
19. A method for the manufacture of a substrate as claimed in any one of
claims 1 to 18 comprising the steps:
a. depositing metal particles from a suspension onto said substrate,
b. rinsing said substrate, and
c. drying said substrate.
20. A method as claimed in claim 19 comprising the step of depositing an
electron donating material on said substrate before the deposition of metal
particles.



Abstract


A Biocompatible Substrate Having an Electron Donating Surface
with Metal Particles Comprising Palladium on Said Surface
A biocompatible substrate having an electron donating surface with metal
particles comprising palladium on said surface is disclosed. The substrate
comprising an electron donating surface with metal particles on said surface,
wherein each metal particle comprises palladium and at least one metal selected
from the group consisting of gold, ruthenium, rhodium, osmium, iridium, and
platinum, wherein the amount of said metal particles on said surface is from 0.001 to
8 µg/cm2. wherein said metal particles have an average size of 10-10000 Å, wherein
said particles are distributed particles on said surface from a colloidal suspension of
the particles; and wherein the metal particles do not form a covering layer.

Documents:

4024-KOLNP-2008-(16-08-2013)-ANNEXURE TO FORM 3.pdf

4024-KOLNP-2008-(16-08-2013)-CORRESPONDENCE.pdf

4024-KOLNP-2008-(16-08-2013)-OTHERS.pdf

4024-KOLNP-2008-(23-09-2013)-ABSTRACT.pdf

4024-KOLNP-2008-(23-09-2013)-ANNEXURE TO FORM 3.pdf

4024-KOLNP-2008-(23-09-2013)-CLAIMS.pdf

4024-KOLNP-2008-(23-09-2013)-CORRESPONDENCE.pdf

4024-KOLNP-2008-(23-09-2013)-DESCRIPTION (COMPLETE).pdf

4024-KOLNP-2008-(23-09-2013)-FORM-2.pdf

4024-KOLNP-2008-(23-09-2013)-OTHERS.pdf

4024-KOLNP-2008-(23-09-2013)-PA.pdf

4024-KOLNP-2008-(23-09-2013)-PETITION UNDER RULE 137.pdf

4024-kolnp-2008-abstract.pdf

4024-KOLNP-2008-ASSIGNMENT-1.1.pdf

4024-KOLNP-2008-ASSIGNMENT.pdf

4024-KOLNP-2008-CANCELLED PAGES.pdf

4024-kolnp-2008-claims.pdf

4024-KOLNP-2008-CORRESPONDENCE-1.1.pdf

4024-KOLNP-2008-CORRESPONDENCE-1.2.pdf

4024-kolnp-2008-correspondence.pdf

4024-kolnp-2008-description (complete).pdf

4024-KOLNP-2008-EXAMINATION REPORT.pdf

4024-kolnp-2008-form 1.pdf

4024-KOLNP-2008-FORM 18-1.1.pdf

4024-KOLNP-2008-FORM 18.pdf

4024-kolnp-2008-form 3.pdf

4024-kolnp-2008-form 5.pdf

4024-KOLNP-2008-GPA-1.1.pdf

4024-KOLNP-2008-GPA.pdf

4024-KOLNP-2008-GRANTED-ABSTRACT.pdf

4024-KOLNP-2008-GRANTED-CLAIMS.pdf

4024-KOLNP-2008-GRANTED-DESCRIPTION (COMPLETE).pdf

4024-KOLNP-2008-GRANTED-FORM 1.pdf

4024-KOLNP-2008-GRANTED-FORM 2.pdf

4024-KOLNP-2008-GRANTED-FORM 3.pdf

4024-KOLNP-2008-GRANTED-FORM 5.pdf

4024-KOLNP-2008-GRANTED-SPECIFICATION-COMPLETE.pdf

4024-kolnp-2008-international publication.pdf

4024-KOLNP-2008-INTERNATIONAL SEARCH REPORT & OTHERS.pdf

4024-kolnp-2008-international search report.pdf

4024-KOLNP-2008-OTHERS.pdf

4024-kolnp-2008-pct priority document notification.pdf

4024-kolnp-2008-pct request form.pdf

4024-KOLNP-2008-PETITION UNDER RULE 137.pdf

4024-KOLNP-2008-REPLY TO EXAMINATION REPORT.pdf

4024-kolnp-2008-specification.pdf

4024-KOLNP-2008-TRANSLATED COPY OF PRIORITY DOCUMENT.pdf


Patent Number 261071
Indian Patent Application Number 4024/KOLNP/2008
PG Journal Number 23/2014
Publication Date 06-Jun-2014
Grant Date 02-Jun-2014
Date of Filing 03-Oct-2008
Name of Patentee BACTIGUARD AB
Applicant Address BOX 5070, 102 42 STOCKHOLM
Inventors:
# Inventor's Name Inventor's Address
1 SODERVALL, BILLY KUNGSGATAN 19, S-285 31 MARKARYD
2 OHRLANDER, MATTIAS PLANTSKOLEVAGEN 15, S-122 38 ENSKEDE
PCT International Classification Number A61L 2/238
PCT International Application Number PCT/SE2007/050225
PCT International Filing date 2007-04-05
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 60/790307 2006-04-07 U.S.A.